Improvement in Measures of Disease Progression With Tafamidis in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT)

被引：0
|
作者：
Hanna, Mazen A.
Fine, Nowell
Gundapaneni, Balarama
Sultan, Marla B.
Witteles, Ronald
机构：
来源：
CIRCULATION | 2021年 / 144卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A12239
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Tafamidis Stabilizes Transthyretin and Improves Clinical Outcomes in Transthyretin Amyloid Cardiomyopathy
    Falk, Rodney
    Maurer, Matthew
    Fedson, Savitri
    Judge, Daniel
    Zeldenrust, Steven
    Quyyumi, Arshed
    Pano, Arian
    Packman, Jeff
    Grogan, Donna
    [J]. JOURNAL OF CARDIAC FAILURE, 2011, 17 (08) : S56 - S56
  • [32] Tafamidis in Transthyretin Amyloid Cardiomyopathy Effects on Transthyretin Stabilization and Clinical Outcomes
    Maurer, Mathew S.
    Grogan, Donna R.
    Judge, Daniel P.
    Mundayat, Rajiv
    Packman, Jeff
    Lombardo, Ilise
    Quyyumi, Arshed A.
    Aarts, Janske
    Falk, Rodney H.
    [J]. CIRCULATION-HEART FAILURE, 2015, 8 (03) : 519 - 526
  • [33] Relationship of tafamidis binding site occupancy, transthyretin stabilization, and disease modification in tafamidis treated transthyretin amyloid cardiomyopathy patients
    Moody, A. T.
    Tess, D. A.
    Li, Z.
    Bulawa, C.
    Fleming, J.
    Maurer, T. S.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 : 956 - 956
  • [34] Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy
    Paton, D. M.
    [J]. DRUGS OF TODAY, 2019, 55 (12) : 727 - 734
  • [35] Role of tafamidis in reducing the effect and progression of transthyretin amyloid cardiomyopathy.
    Konda, Raghunandan
    Vadala, David
    Rafae, Abdul
    Isa, Sakiru
    Devarkonda, Vishal
    Kesari, Kavitha
    Kunadi, Arvind
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy
    Falk, Rodney H.
    Haddad, Mia
    Walker, Crystal R.
    Dorbala, Sharmila
    Cuddy, Sarah A. M.
    [J]. JACC: CARDIOONCOLOGY, 2021, 3 (04): : 580 - 586
  • [37] Free Light-Chain Levels in Patients with Transthyretin Amyloid Cardiomyopathy in Attr-ACT
    Hoffman, James E.
    Sultan, Marla B.
    Gundapaneni, Balarama
    Witteles, Ronald
    [J]. BLOOD, 2021, 138 : 3787 - +
  • [38] Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study
    Garcia-Pavia, Pablo
    Sultan, Marla B.
    Gundapaneni, Balarama
    Sekijima, Yoshiki
    Perfetto, Federico
    Hanna, Mazen
    Witteles, Ronald
    [J]. JACC-HEART FAILURE, 2024, 12 (01) : 150 - 160
  • [39] Clinical characteristics, patient selection and clinical outcomes of tafamidis treatment in transthyretin amyloidosis cardiomyopathy
    Takashio, S.
    Morioka, M.
    Fujiyama, A.
    Oike, F.
    Hanatani, S.
    Usuku, H.
    Yamamoto, E.
    Matsushita, K.
    Tsujita, K.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 : 964 - 964
  • [40] TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY DISEASE STAGING SYSTEMS FOR PATIENTS TREATED WITH TAFAMIDIS THERAPY
    Shahi, Karan
    Miller, Robert J. H.
    Dykstra, Steven
    Feng, Yuanchao
    Howlett, Jonathan G.
    Kassam, Shireen
    Veenhuyzen, Jan
    White, James
    Fine, Nowell Mark
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 686 - 686
12345